Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Underestimation
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| P/E |
0/10
|
0 | 35.42 | -100% | -18.83 | -100% |
| P/S |
|
5.89 | 7.59 | -22.44% |
|
|
| P/BV |
|
5.34 | 3.68 | 44.85% |
|
|
| P/FCF |
|
-56.04 | 55.3 | -201.34% |
|
|
| Ev/Ebitda |
|
-30.13 | 2.91 | -1136.14% |
|
|
| Ev/S |
|
15.59 | 23.72 | -34.24% |
|
|
| Ev/FCF |
|
-55 | 63.78 | -186.24% |
|
|
| E/P |
|
-0.0336 | 0.0326 | -202.97% |
|
|
Efficiency
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Ebitda margin |
0/10
|
-113.25 | -11.9 | 851.56% | 0 | 0% |
| ROE |
|
-42.6 | 5.19 | -921.32% |
|
|
| ROA |
|
-15.56 | 3.47 | -548.53% |
|
|
| ROIC |
|
0 | 0 | 0% |
|
|
| ROS |
|
-53.42 | -11.49 | 365.05% |
|
|
| ROCE |
|
0 | 6.04 | -100% |
|
|
Debt
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Debt/Ebitda |
10/10
|
-0.8914 | 0.7755 | -214.95% | -0.8914 | 0% |
| Nеt Debt/Ebitda |
|
0 | 0.0127 | -100% |
|
|
| Debt/Ratio |
|
0.1696 | 0.1229 | 38.01% |
|
|
| Debt/Equity |
|
0.2597 | 0.802 | -67.62% |
|
|
| Debt/Net Income |
|
-1.08 | 1.76 | -161.7% |
|
|
Dividends
| Parameter | Grade | Value | Sector average | Difference with sector, % | Average for 5 years | Difference from average, % |
|---|---|---|---|---|---|---|
| Dividend yield |
0/10
|
0 | 2.43 | -100% | 0 | 0% |
| Number of years of dividend growth |
|
0 | 1.21 | -100% | ||
| DSI |
|
0 | 0.563 | -100% |
|
|
| Average dividend growth |
|
0 | 3.2 | -100% |
|
|
| Average percentage for 5 years |
|
0 | 1.82 | -100% |
|
|
| Average percentage for payments |
|
0 | 23.96 | -100% |
|
|
| Difference from average difference in sector |
|
-2.43 |
Growth impulse
| Parameter | Grade | Value | Sector average | Difference with sector, % | ||
|---|---|---|---|---|---|---|
| Growth impulse Revenue in 5 years |
10/10
|
182.76 | 28.69 | 537.02% | ||
| Growth impulse Ebitda in 5 years |
|
0 | -40.52 | -100% | ||
| Growth impulse Net Income in 5 years |
|
-10.54 | 94.84 | -111.11% | ||
| Growth impulse FCF in 5 years |
|
-61.77 | 91.41 | -167.57% | ||
| Growth impulse EPS in 5 years |
|
-10.96 | -118.14 | -90.72% |
IP Score
2.78/10
